Tanezumab: A In-depth Dive into the 880266-57-9 Reagent Substance
Tanezumab, identified by the research designation 880266-57-9, represents a monoclonal antibody compound demonstrating significant promise in alleviating chronic osteoarthritis pain. This engineered antibody uniquely targets pain growth protein, reducing its function and thereby reducing inflammation within affected areas . The ongoing data surrounding 880266-57-9 highlights its power to provide noticeable suffering alleviation while perhaps avoiding the requirement for opioid analgesics. Further research are currently underway to thoroughly determine its long-term well-being and effectiveness .
Comprehending Tanezumab's Part in Ache Alleviation: An Antibody Perspective
Tanezumab, a unique therapeutic approach, offers a unique pathway in long-term pain alleviation. As a humanized antibody, it selectively targets and blocks nerve growth factor (NGF), a important molecule participating in sensory pain signaling. Unlike traditional narcotic medications, tanezumab’s antibody mechanism allows for a greater precise action, possibly decreasing the likelihood of some frequent side consequences connected with systemic pain alleviation. However, its protein nature necessitates a thorough assessment of potential body's reactions and extended impacts when administered within a complete pain management strategy.
Tanezumab Solution (880266-57-9): Purity , Grade & Applications
The Tanezumab Solution with the identifier 880266-57-9 is a essential component in various biomedical applications, particularly concerning osteoarthritis treatment development. Achieving a high degree of consistency is paramount; therefore, rigorous analysis protocols are employed to guarantee its read more appropriateness for specific use. Our manufacturing process focuses on ensuring purity , employing sophisticated separation techniques to remove contaminants . Typical parameters include a >95% purity level as determined by Chromatography and comprehensive testing for protein integrity. The main uses revolve around its role as a scientific resource for investigating the mechanisms of arthritis progression and next-generation medical solutions.
- Research Investigations
- Medical Development
- Pathway Studies
A Study Behind Tanezumab:
Tanezumab, identified through the molecular identifier 880266-57-9, represents a innovative biological immunoglobulin targeting sensory development agent receptor (NGF). Its process of function revolves around specifically connecting to NGF, consequently blocking its activity and following communication transduction. Scientists have shown that this biological agent presents potential for managing persistent pain, particularly in conditions like arthritic conditions and lower back pain. Additional studies are underway to thoroughly characterize its impact and well-being data.
Recent Developments in Tanezumab Research: Focusing on the The Reagent
Current analyses surrounding tanezumab, a experimental therapeutic molecule, are increasingly focused on defining the role of the particular reagent, the reagent. The identification and detailed evaluation of the biological entity seems crucial for improving tanezumab's performance and minimizing anticipated undesirable reactions. Preliminary findings reveal that the reagent plays a significant part in tanezumab's process of action. More investigations are required to entirely understand the reagent’s effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}